JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, L3
CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Condensed Consolidated Interim Financial Statements As of June 30, 2026
Announces ADS Ratio Change Effective August 21, 2026
Annual and Transition Report of Foreign Private Issuers
Q1
FY 2022
Notice of Late Filing for Annual Report
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
No filings found
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
NT 20-F